title: Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial.
authors.forename: Babafemi O
authors.initials: BO
authors.lastname: Taiwo
authors.forename: John A
authors.initials: JA
authors.lastname: Idoko
authors.forename: Anne-Geneviève
authors.initials: AG
authors.lastname: Marcelin
authors.forename: Ihedinachi
authors.initials: I
authors.lastname: Otoh
authors.forename: Susheel
authors.initials: S
authors.lastname: Reddy
authors.forename: Paul G
authors.initials: PG
authors.lastname: Iyaji
authors.forename: Oche
authors.initials: O
authors.lastname: Agbaji
authors.forename: Sudhir
authors.initials: S
authors.lastname: Penugonda
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Agaba
authors.forename: Robert L
authors.initials: RL
authors.lastname: Murphy
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D020125:Mutation, Missense; D009549:Nigeria
chemical_list: D019380:Anti-HIV Agents; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase